Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Myriad Genetics Q1 2026 Earnings Call - Hereditary Cancer Growth Fuels Confidence as MRD and FirstGene Launches Set Stage for 2026 Acceleration
Myriad Genetics reported Q1 2026 revenue of $200.4 million, landing in line with guidance, driven by double-digit volume growth in hereditary cancer testing and strong momentum in its mental health fr...
- Q1 2026 revenue came in at $200.4 million, within the low end of the $200-$202 million guidance range, representing 2% year-over-year growth.
- Hereditary cancer testing volume surged 14% year-over-year, with the unaffected population growing 16% and the affected population growing 10%, outpacing market rates.
- GeneSight mental health test revenue jumped 24% year-over-year to $38.3 million, supported by 7% volume growth and improved reimbursement dynamics from biomarker legislation.
- +7 more takeaways
Dentsply Sirona Q1 2026 Earnings Call - Return to Growth Plan Faces Headwinds Amid Tariffs and Execution Shifts
Dentsply Sirona reported Q1 2026 revenue of $880 million, essentially flat on a reported basis but down 6.7% on a constant currency basis. The decline was driven by tough comps, tariff impacts, and a ...
- Q1 2026 revenue came in at $880 million, up 0.1% as reported but down 6.7% on a constant currency basis, reflecting tough comps, tariff headwinds, and a one-time institutional installation in the prior year.
- Adjusted EBITDA margins contracted 430 basis points, driven by a 560 basis point gross margin decline from lower volumes, unfavorable sales mix, and tariff impacts.
- Operating expenses fell by $20 million on a constant currency basis, signaling early progress in the Return to Growth action plan’s cost restructuring efforts.
- +7 more takeaways
Talen Energy Q1 2026 Earnings Call - Cornerstone Acquisition Financing Locked In, 2027/2028 FCF Per Share Outlook Raised
Talen Energy reported a strong first quarter of 2026, with adjusted EBITDA more than doubling and adjusted free cash flow quadrupling year-over-year, driven by the recent acquisition of Freedom and Gu...
- Q1 2026 Adjusted EBITDA reached $473 million and adjusted free cash flow hit $350 million, with year-over-year growth more than doubling and quadrupling respectively, driven by the Freedom and Guernsey acquisitions and higher market prices.
- Talen Energy secured $4 billion in senior unsecured notes for the pending Cornerstone acquisition, reducing the cost of capital and allowing the company to close the deal once regulatory approvals are finalized.
- The company reaffirmed its 2026 guidance, with adjusted EBITDA expected between $1.75 billion and $2.05 billion and adjusted free cash flow between $980 million and $1.18 billion, excluding Cornerstone.
- +7 more takeaways
GRAIL Q1 2026 Earnings Call - Galleri Volume Surges 50% Amid Epic Integration and ASCO Data Anticipation
GRAIL reported strong first quarter 2026 results, with Galleri test volumes jumping 50% year-over-year to over 56,000 tests and screening revenue climbing 37% to $39.8 million. The company continues t...
- Galleri test volumes surged 50% year-over-year in Q1 2026, surpassing 56,000 tests, while screening revenue grew 37% to $39.8 million.
- Total revenue reached $40.8 million, up 28% year-over-year, driven by a 37% increase in screening revenue and $1 million in development services.
- Net loss improved 12% to $93.2 million, with adjusted EBITDA narrowing 19% to negative $79.9 million, reflecting improved operational leverage.
- +7 more takeaways
"Hinge Health" Q1 2026 Earnings Call - Strong Q1 Results, Raised Guidance, and Migraine Program Launch
Hinge Health delivered a strong start to 2026, with Q1 revenue of $182 million, up 47% year-over-year, significantly beating guidance. The company raised its full-year revenue guidance to $798-$804 mi...
- Revenue of $182 million in Q1 2026, up 47% year-over-year, significantly exceeding the guidance range of $171-$173 million.
- LTM calculated billings reached $770 million, a 52% year-over-year increase, driven by higher eligible lives and improved member yields.
- Gross margin expanded to 85% from 81% in Q1 2025, reflecting AI-driven care team efficiency and hardware optimization.
- +12 more takeaways
Energy Vault Q1 2026 Earnings Call - Backlog Surges to $1.35 Billion as Shift to IPP Model Accelerates
Energy Vault delivered a 156% year-over-year revenue increase in Q1 2026, driven by a decisive pivot from project-based energy storage sales to a vertically integrated, build-own-operate infrastructur...
- Record backlog growth: Contracted backlog surged 108% year-over-year to $1.35 billion, with over 80% now tied to own-and-operate assets, signaling a successful transition from episodic project revenue to long-term infrastructure cash flows.
- Revenue acceleration: Q1 2026 revenue jumped 156% year-over-year to $21.9 million, driven by higher energy storage deliveries and initial contributions from the Asset Vault portfolio.
- Asset base expansion: Total megawatts under control, construction, or operation exceeded 1 GW, nearly five times year-over-year, providing a foundation for recurring revenue as projects reach commercial operation.
- +7 more takeaways
Emerson Electric Q2 2026 Earnings Call - Software & Systems Lead Growth Amid Middle East Disruption
Emerson Electric reported a resilient second quarter despite a direct hit from the Middle East conflict, which shaved a full point off underlying sales. The company’s core engine remains its software ...
- Underlying orders grew 5% in Q2, led by an 18% surge in Software & Systems orders, driven by secular demand in power, life sciences, and aerospace.
- Test & Measurement sales jumped 12% year-over-year, outpacing expectations and supported by strength in semiconductors, aerospace, and defense.
- Software and Systems reported underlying sales growth of 1%, excluding a 4.5% headwind from a software contract renewal dynamic that also dragged on margins.
- +7 more takeaways
TrueBlue Inc Q1 2026 Earnings Call - Energy Sector Revenue Doubles as Data Center Demand Surges
TrueBlue delivered Q1 2026 revenue of $399 million, up 8% year-over-year, landing at the high end of its guidance. The standout driver was PeopleReady’s energy vertical, which more than doubled for th...
- Revenue reached $399 million, up 8% year-over-year and near the high end of guidance.
- PeopleReady’s energy vertical revenue more than doubled for the third consecutive quarter, driven by data center construction and renewable energy projects.
- Data center power needs now represent approximately one-third of TrueBlue’s active energy projects, highlighting a major secular growth driver.
- +7 more takeaways
Alphatec Spine (ATEC) Q1 2026 Earnings Call - Surgical Growth Outpaces EOS Shortfall, EBITDA Surges 97%
Alphatec Spine delivered $192 million in Q1 2026 revenue, up 14% year-over-year, with surgical revenue growing 17% to $178 million. The top line missed internal expectations, primarily due to a $3 mil...
- Total Q1 2026 revenue came in at $192 million, up 14% year-over-year, missing internal expectations due to a shortfall in EOS sales performance.
- Surgical revenue grew 17% year-over-year to $178 million, driven by a 21% increase in procedural volume and 23% growth in new surgeon adoption.
- EOS revenue was $14 million, down $3 million year-over-year, as fewer system deliveries led to lower revenue recognition for the quarter.
- +7 more takeaways
QuidelOrtho Q1 2026 Earnings Call - Respiratory Weakness and China Pricing Headwinds Offset by Strategic Product Launches and Margin Expansion
QuidelOrtho reported a softer first quarter driven by a significantly weaker respiratory season and distributor caution ahead of pending China IVD pricing guidelines. Total revenue came in at $620 mil...
- Respiratory season weakness drove a sharp decline in Q1 revenue, with influenza-like illness visits down 30% year-over-year, impacting both QuidelOrtho and the broader industry.
- Total reported revenue for Q1 2026 was $620 million, with non-respiratory revenue at $552 million, excluding the Donor Screening business.
- Management tethered full-year 2026 revenue guidance to the low end of previous estimates, citing approximately $75 million in headwinds split between respiratory weakness and China market pauses.
- +13 more takeaways